ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,180.74
      1.03%
      US Tech 100
      17,599.60
      1.04%
      Dow Jones
      38,852.27
      0.46%
      Brent Oil
      83.455
      -0.02%
      Bitcoin
      63,281.79
      0.18%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. USOTC
      6. Silence Therapeutics PLC (PK) (SLNCF)

      7. Silence Therapeutics PLC (PK) (SLNCF) News

      SLNCF

      Silence Therapeutics (PK) (SLNCF)

      Silence Therapeutics PLC (PK)
      		Date:
      Sort by:
       Showing the most relevant articles for your search:USOTC:SLNCF
      DateTimeSourceHeadlineSymbolCompany
      12/01/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
      11/01/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
      08/16/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
      08/14/20235:01PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]USOTC:SLNCFSilence Therapeutics PLC (PK)
      07/03/20237:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:SLNCFSilence Therapeutics PLC (PK)
      05/16/20234:02PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      05/01/20237:32AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      03/28/20238:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      02/08/20233:10PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:SLNCFSilence Therapeutics PLC (PK)
      01/12/20234:31PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      11/10/20228:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      10/20/20224:02PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)USOTC:SLNCFSilence Therapeutics PLC (PK)
      09/29/20228:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      08/22/20224:14PMEdgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:SLNCFSilence Therapeutics PLC (PK)
      08/19/20224:31PMEdgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:SLNCFSilence Therapeutics PLC (PK)
      08/12/20221:32PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)USOTC:SLNCFSilence Therapeutics PLC (PK)
      08/12/20226:11AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      08/11/20225:05PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      06/15/20224:33PMEdgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)USOTC:SLNCFSilence Therapeutics PLC (PK)
      05/16/20228:34AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      05/16/20228:33AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      04/25/20228:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      04/04/20228:31AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      03/23/20228:30AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      03/17/202212:32PMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)USOTC:SLNCFSilence Therapeutics PLC (PK)
      02/22/20226:52AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
      02/14/20225:23PMEdgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:SLNCFSilence Therapeutics PLC (PK)
      02/14/20225:12PMEdgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:SLNCFSilence Therapeutics PLC (PK)
      02/10/20224:47PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:SLNCFSilence Therapeutics PLC (PK)
      02/09/20227:30AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)USOTC:SLNCFSilence Therapeutics PLC (PK)
       Showing the most relevant articles for your search:USOTC:SLNCF